Has the CSL share price got further to fall?

ASX experts weigh in on what's next for CSL.

| More on:
Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Well, things were looking up for the CSL Ltd (ASX: CSL) share price. Until 12 February earlier this month, that is. 

Between late October and 12 February, CSL shares were on a tear. This ASX 200 healthcare stock rose more than 32% between those two dates. But after the company released some bitterly disappointing test results for a new cardiovascular drug, investors lost a lot of their confidence.

Since 12 February, CSL shares have tanked by more than 6.6%, falling from over $300 each to the $285.50 we see today (at market close).

Not even a confident earnings report earlier this month could restore investor enthusiasm. As we covered at the time, those earnings revealed that CSL was able to record an 11% rise in revenues, as well as a 20% increase in net profits for the six months ending 31 December. Investors were also treated to a 12% dividend pay rise.

Check out the CSL share price's movements below for yourself:

So with CSL shares coming off the boil and seemingly not getting back on, ASX investors might be asking themselves whether CSL shares have further to fall. After all, it was only in late October that this healthcare giant got as low as $228.65 a share.

Does the CSL share price have further to fall?

Well, let's see what some ASX experts think.

Following the release of CSL's earnings, my Fool colleague James covered the views of ASX broker Morgans. Morgans did trim its price target for CSL shares following its disappointing trial results. But it still rates the company as an add following its earnings, with a price target of $315.40. If realised, that would represent an upside of more than 10% from current prices.

Morgans was happy with what CSL reported earlier this month and evidently sees significant value in the company's share price at its current levels.

But Morgans isn't the only expert that is eyeing off the healthcare giant right now. eToro analyst Josh Gilbert shares a positive view. Here's some of what he recently said about CSL right now:

CSL shareholders will have reason to smile today with the release of a solid half-yearly report… [These] results show that the business continues to move in the right direction, and there is plenty to be positive about. With solid profit growth, a healthy dividend, solid guidance, and interest rate cuts not far away, CSL will be on investors' watchlists.

So it appears that at least two ASX experts reckon CSL shares are more likely to head up than down going forward. But, as always, we'll have to wait and see if that turns out to be the case.

Motley Fool contributor Sebastian Bowen has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »